Therapeutic flag Cosmetic cross-reference

Lipoic Acid, Alpha

CAS 1077-28-7

Lipoic Acid, Alpha (CAS 1077-28-7) is a Phase 3 pharmaceutical compound with 4 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
8
SOURCE DrugCentral / FAERS
Adverse signals
0
SOURCE IUPHAR / PharmGKB
PubMed IDs
0
SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Lipoic Acid, Alpha
CAS Number
1077-28-7
UNII
73Y7P0K73Y
InChIKey
AGBQKNBQESQNJD-UHFFFAOYSA-N
ChEMBL ID
CHEMBL33864
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
.ALPHA.-LIPOIC ACIDTHIOCTIC ACID
natural producttherapeutic flag
SOURCE ChEMBL 36 B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3
Late-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL33864 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE ChEMBL 36 activities + assays 8 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- GI50 93832.33127272727 nM 55 -
- Potency 21073.195238095235 nM 35 -
- AC50 28011.590909090908 nM 33 -
- IC50 27095.972857142857 nM 13 -
Acetylcholinesterase
Enzyme
IC50 9 - Homo sapiens
SUMO-activating enzyme
Enzyme
IC50 5.32 - Homo sapiens
Bifunctional protein GlmU
Enzyme
IC50 5.41 - Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)
TAR DNA-binding protein 43
Unclassified
IC50 4.7 - Homo sapiens
SOURCE RxNorm drug names 2 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
.ALPHA.-LIPOIC ACID 6417 SU MTHSPL
THIOCTIC ACID 6417 SU MTHSPL
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Lipoic Acid, Alpha used for in pharmaceutical contexts?

Lipoic Acid, Alpha (CAS 1077-28-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Lipoic Acid, Alpha?

No adverse-event association or SIDER side-effect rows are rendered for Lipoic Acid, Alpha in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Lipoic Acid, Alpha also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Alpha-Lipoic Acid with EU status "permitted".

What clinical phase is Lipoic Acid, Alpha in?

Lipoic Acid, Alpha is rendered with ChEMBL max phase 3.

What bioactivity targets are documented for Lipoic Acid, Alpha?

Lipoic Acid, Alpha has 8 bioactivity rows in this page query. Rendered target entries include Acetylcholinesterase, SUMO-activating enzyme, Bifunctional protein GlmU, TAR DNA-binding protein 43.